August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
12 citations
,
February 2022 in “Frontiers in Pharmacology” Asparagus racemosus and Withania somnifera can help reduce side effects of a cancer drug.
4 citations
,
September 2024 in “BMC Cancer” July 2023 in “Journal of the European Academy of Dermatology and Venereology” Anti-IL17A therapy reduced venous leg ulcer size by 64% without major side effects.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
16 citations
,
October 2023 in “Molecular cancer” New treatments like nanotechnology show promise in improving skin cancer therapy.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
35 citations
,
October 2021 in “Journal of the European Academy of Dermatology and Venereology” COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
27 citations
,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
7 citations
,
November 2021 in “JAAD Case Reports” Mogamulizumab can cause hair loss and skin rashes.
1 citations
,
October 2002 in “The Journal of Urology” September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
36 citations
,
June 2016 in “Journal of dermatological treatment” The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.
October 2025 in “Plastic & Reconstructive Surgery” MNC-QQ cell therapy improved hair growth and quality of life in men with androgenic alopecia without adverse effects.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
3 citations
,
January 2011 in “American Journal of Hematology” Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.
7 citations
,
December 2016 in “Journal of the American Academy of Dermatology” NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
April 2024 in “Al-Azhar International Medical Journal /Al-Azhar International Medical Journal” Combining fractional CO2 laser or microneedling with 5-FU is more effective and safer for treating vitiligo.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
January 2012 in “Chinese Clinical Oncology” Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.